- Email: [email protected]
Update on allergic and nonallergic rhinitis
Tuesday, September 21, 2004
6:30 AM to 7:45 AM Room JJCC Special Events Hall 1DMR •
Chronic Ear Disease in Children: An Audience Interactive Panel Discussion
Peter S Roland, MD (moderator); William H Slattery, III, MD; Michael D Poole, MD PhD; Joseph E Dohar, MD; Patrick J Antonelli, MD Dallas TX; Los Angeles CA; Houston TX; Pittsburgh PA; Gainesville FL The symposium will consist of a panel discussion about management of chronic ear disease in children. There will be no formal presentation. The symposium will consist of lively interaction among panelists. Two cases will be presented: The cases will evolve during the discussion as initial treatment fails. Case 1. A case of posttympanostomy tube otorrhea. The following questions will be addressed to the panel: (1) What is the natural history of the disease? Is treatment always indicated? If not, what circumstances should define when treatment is necessary? What is your initial management? (2) How long do you wait to see if initial treatment proceeds and if it fails, what do you do next? What is the role of tube removal, adenoidectomy, culture and C&S, immune workup and surgery? (3) If fungal organisms are identified on culture, what is their significance? Are they pathogens, saprophytes or contaminants? How often are they the result of previous antibacterial therapy? How should fungal organisms be managed? Case 2. Established CSOM with an aural polyp. The following questions will be addressed to the panel: (1) What puts children at risk for CSOM? Can the risk be reduced? (2) What is the differential diagnosis of an aural polyp? How is it managed? (3) How important is aural toilet and how is it
best achieved? (4) What are the roles of topical and systemic antibiotic therapy? What antibiotics are most useful? Can oral quinolones be used in children? (5) How important is granulation tissue and how is it best managed? (6) What is the role of imaging? What imaging modalities are most useful? What are the key points of interpretation? (7) When is surgery indicated? What operations are most useful? What are the key features of successful operations? For each case, as opportunity arises, panelists will be asked about the significance of biofilms and about new or investigational interventions. The last 15–20 minutes will be set aside for questions for the audience.
6:30 AM to 7:45 AM Room JJCC Hall 3A •
Update on Allergic and Nonallergic Rhinitis
Robert M Naclerio, MD (moderator) Chicago IL Rhinitis, inflammation of the nasal mucosa, can be classified into allergic (IgE-mediated) and nonallergic forms. These problems affect more than 50 million Americans, interfere with the quality of life, initiate about 20 million physician visits, and cost the US economy billions of dollars each year. Researchers have investigated the pathophysiology of rhinitis with nasal lavage, scrapings, and biopsies following antigenic and nonantigenic nasal stimulation. Similar studies have been performed during natural disease. Biochemical and cytologic information is relatively easily obtainable, and pharmacologic manipulations can be reliably monitored. The therapy for treatment continues to expand and change. The latest treatment options will be discussed relative to pathophysiology and overall guidelines for management. Handouts of slides will be available.
8:00 AM to 9:30 AM Room JJCC 1A12
8:00 AM
•
Daniel M Kaplan, MD (presenter); Mordechai Kraus, MD
Bilateral Benign Paroxysmal Positional Vertigo
Scientific Session: Otology/Neurotology Moderators: Patrick J. Antonelli, Woodson, MD
MD,
B. Tucker
P90 Otolaryngology–Head and Neck Surgery
Toronto Canada; Beer Sheva Israel
Objectives: Although bilateral involvement in benign paroxysmal positional vertigo (BiBPPV) is not uncommon, there
August 2004
TUESDAY
Foundation Annual Meeting Symposia (FAMS) Tuesday, September 21
6:30 AM to 7:45 AM Room JJCC Special Events Hall 1DMR •
Chronic Ear Disease in Children: An Audience Interactive Panel Discussion
Peter S Roland, MD (moderator); William H Slattery, III, MD; Michael D Poole, MD PhD; Joseph E Dohar, MD; Patrick J Antonelli, MD Dallas TX; Los Angeles CA; Houston TX; Pittsburgh PA; Gainesville FL The symposium will consist of a panel discussion about management of chronic ear disease in children. There will be no formal presentation. The symposium will consist of lively interaction among panelists. Two cases will be presented: The cases will evolve during the discussion as initial treatment fails. Case 1. A case of posttympanostomy tube otorrhea. The following questions will be addressed to the panel: (1) What is the natural history of the disease? Is treatment always indicated? If not, what circumstances should define when treatment is necessary? What is your initial management? (2) How long do you wait to see if initial treatment proceeds and if it fails, what do you do next? What is the role of tube removal, adenoidectomy, culture and C&S, immune workup and surgery? (3) If fungal organisms are identified on culture, what is their significance? Are they pathogens, saprophytes or contaminants? How often are they the result of previous antibacterial therapy? How should fungal organisms be managed? Case 2. Established CSOM with an aural polyp. The following questions will be addressed to the panel: (1) What puts children at risk for CSOM? Can the risk be reduced? (2) What is the differential diagnosis of an aural polyp? How is it managed? (3) How important is aural toilet and how is it
best achieved? (4) What are the roles of topical and systemic antibiotic therapy? What antibiotics are most useful? Can oral quinolones be used in children? (5) How important is granulation tissue and how is it best managed? (6) What is the role of imaging? What imaging modalities are most useful? What are the key points of interpretation? (7) When is surgery indicated? What operations are most useful? What are the key features of successful operations? For each case, as opportunity arises, panelists will be asked about the significance of biofilms and about new or investigational interventions. The last 15–20 minutes will be set aside for questions for the audience.
6:30 AM to 7:45 AM Room JJCC Hall 3A •
Update on Allergic and Nonallergic Rhinitis
Robert M Naclerio, MD (moderator) Chicago IL Rhinitis, inflammation of the nasal mucosa, can be classified into allergic (IgE-mediated) and nonallergic forms. These problems affect more than 50 million Americans, interfere with the quality of life, initiate about 20 million physician visits, and cost the US economy billions of dollars each year. Researchers have investigated the pathophysiology of rhinitis with nasal lavage, scrapings, and biopsies following antigenic and nonantigenic nasal stimulation. Similar studies have been performed during natural disease. Biochemical and cytologic information is relatively easily obtainable, and pharmacologic manipulations can be reliably monitored. The therapy for treatment continues to expand and change. The latest treatment options will be discussed relative to pathophysiology and overall guidelines for management. Handouts of slides will be available.
8:00 AM to 9:30 AM Room JJCC 1A12
8:00 AM
•
Daniel M Kaplan, MD (presenter); Mordechai Kraus, MD
Bilateral Benign Paroxysmal Positional Vertigo
Scientific Session: Otology/Neurotology Moderators: Patrick J. Antonelli, Woodson, MD
MD,
B. Tucker
P90 Otolaryngology–Head and Neck Surgery
Toronto Canada; Beer Sheva Israel
Objectives: Although bilateral involvement in benign paroxysmal positional vertigo (BiBPPV) is not uncommon, there
August 2004
TUESDAY
Foundation Annual Meeting Symposia (FAMS) Tuesday, September 21